Constitutive AKT activation in follicular lymphoma

[31] Silliman N(2011)CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 591-7689

[32] Ptak J(2010)Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of Phosphatidylinositol 3-Kinase P110 δ, in patients with relapsed or refractory Non-Hodgkin lymphoma [abstract] Blood 116 1777-929

[33] Szabo S(2012)CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies Expert Opin Investig Drugs 21 15-518

[34] Yan H(2009)Dok-4 is a novel negative regulator of T cell activation J Immunol 182 7681-86

[35] Gazdar A(2005)Oncogenic PI3K deregulates transcription and translation Nat Rev Cancer 5 921-376

[36] Powell SM(2003)Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas Brain Pathol 13 507-19241

[37] Riggins GJ(2005)Activation of AKT kinases in cancer: implications for therapeutic targeting Adv Cancer Res 94 29-763

[38] Willson JK(2006)Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations Leukemia 20 374-24

[39] Markowitz S(1997)p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes J Biol Chem 272 19236-undefined

[40] Kinzler KW(2002)A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation J Exp Med 196 753-undefined

[31] Silliman N(2011)CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 591-7689

[32] Ptak J(2010)Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of Phosphatidylinositol 3-Kinase P110 δ, in patients with relapsed or refractory Non-Hodgkin lymphoma [abstract] Blood 116 1777-929

[33] Szabo S(2012)CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies Expert Opin Investig Drugs 21 15-518

[34] Yan H(2009)Dok-4 is a novel negative regulator of T cell activation J Immunol 182 7681-86

[35] Gazdar A(2005)Oncogenic PI3K deregulates transcription and translation Nat Rev Cancer 5 921-376

[36] Powell SM(2003)Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas Brain Pathol 13 507-19241

[37] Riggins GJ(2005)Activation of AKT kinases in cancer: implications for therapeutic targeting Adv Cancer Res 94 29-763

[38] Willson JK(2006)Constitutive phosphoinositide 3-kinase activation in acute myeloid leukemia is not due to p110delta mutations Leukemia 20 374-24

[39] Markowitz S(1997)p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes J Biol Chem 272 19236-undefined

[40] Kinzler KW(2002)A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation J Exp Med 196 753-undefined